Staar Surgical (STAA) Cash & Equivalents (2010 - 2026)

Staar Surgical (STAA) has 17 years of Cash & Equivalents data on file, last reported at $131.9 million in Q2 2026.

• For the quarter ending Q2 2026, Cash & Equivalents fell 23.83% year-over-year to $131.9 million; the trailing twelve-month figure through Apr 2026 stood at $131.9 million (down 23.83% YoY), and the FY2026 full-year result was $153.2 million, up 6.24% from the prior year.
• Cash & Equivalents for Q2 2026 stood at $131.9 million, down from $153.2 million in the prior quarter.
• Across five years, Cash & Equivalents topped out at $224.0 million in Q1 2024 and bottomed at $86.5 million in Q4 2022.
• The 5-year median for Cash & Equivalents is $164.0 million (2024), against an average of $154.9 million.
• The widest annual swing landed in 2022, when Cash & Equivalents plunged 56.7%; it then soared 149.0% in 2024.
• A 5-year view of Cash & Equivalents shows it stood at $86.5 million in 2022, then soared by 111.65% to $183.0 million in 2023, then dropped by 21.24% to $144.2 million in 2024, then rose by 22.19% to $176.2 million in 2025, then retreated by 25.14% to $131.9 million in 2026.
• The last three Cash & Equivalents figures came in at $131.9 million (Q2 2026), $153.2 million (Q1 2026), and $176.2 million (Q3 2025), per Business Quant data.

Peer Comparison